# A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients

Source: https://onco.cc/trials/nct04024696/  
OnCo record `nct04024696` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Abexinostat in hodgkin lymphoma and non-hodgkin lymphoma, run by Xynomic Pharmaceuticals, Inc., active and no longer recruiting.

## Summary

A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients is a phase 1/2 interventional study registered as NCT04024696 by Xynomic Pharmaceuticals, Inc., with 12 participants enrolled, started 2020-01-08 and due to reach its primary completion in 2024-12-30. Interventions recorded: Abexinostat. Conditions listed: Non Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04024696
- Phase: 1/2
- Setting: An Open-Label, Non-Randomized Clinical Study to Evaluate Pharmacokinetic (PK) Profiles, Safety, and Tolerability of Abexinostat Monotherapy in Patients With Non-Hodgkin's Lymphoma Who Have Failed Standard of Care
- Sponsor: Xynomic Pharmaceuticals, Inc.
- Enrolled: 12

## Sources

- ClinicalTrials.gov NCT04024696: https://clinicaltrials.gov/study/NCT04024696

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Abexinostat](https://onco.cc/drugs/abexinostat/)

---
JSON: https://onco.cc/api/v1/entities/nct04024696.json